1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study

Abstract

Background: While OS remains the gold standard in first-line (1L) mRCC, surrogate endpoints that correlate with OS in the short term can be utilized to expedite drug testing and accelerate approval. We aimed to evaluate time-to-next therapy (TTNT) and best overall response (BOR) as potential intermediate endpoints (IEs).